Physician profile
Cathleen Mae Mccabe
NPI 1700840493
$1,983,133.62
in general payments reported to CMS, 2019-2025
45 companies · $967K in 2025
The $967K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $96K · 2020: $77K · 2021: $118K · 2022: $211K · 2023: $155K · 2024: $359K · 2025: $967K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $987K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $307K · Travel and Lodging: $116K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $43K · Food and Beverage: $26K · Charitable Contribution: $1,637 · Gift: $77.25 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $986,745.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $307,496.29 |
| Travel and Lodging | $115,543.14 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $42,985.58 |
| Food and Beverage | $26,173.05 |
| Charitable Contribution | $1,636.98 |
| Gift | $77.25 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,218,716.43 | 2022-2025 | Miebo, Xiidra, Elios Glaucoma Laser System |
| Alcon Vision LLC | $253,030.45 | 2019-2025 | Acrysof Iq Vivity, Acrysof Iq Panoptix Uv Iol, Clareon |
| Novartis Pharmaceuticals Corporation | $88,435.25 | 2019-2023 | |
| Alcon Research LLC | $81,479.33 | 2019-2024 | Centurion, Acrysof Iq Vivity, Clareon |
| Allergan, INC. | $63,485.58 | 2019-2022 | |
| Lensar, INC. | $45,908.09 | 2020-2024 | Lensar Laser System |
| Ivantis, INC | $32,148.27 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29,802.79 | 2019-2021 | |
| Sight Sciences, INC. | $27,254.07 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Tarsus Pharmaceuticals, INC. | $26,735.07 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec, INC. | $23,293.95 | 2019-2025 | Iolmaster 700, Veracity Surgical, Artevo 800 |
| Abbvie INC. | $22,454.71 | 2022-2024 | |
| Ocular Therapeutix, INC. | $20,533.86 | 2019-2025 | Dextenza |
| Eyepoint US, INC. | $13,410.85 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $6,598.14 | 2022-2025 | Omidria, Rayone Spheric, Rayone Emv |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $5,952.13 | 2019-2021 | |
| Beaver-Visitec International, INC. | $5,950.00 | 2023-2024 | |
| Carl Zeiss Meditec Cataract Technology INC. | $2,618.88 | 2021 | |
| Tearlab Corp | $2,234.07 | 2023-2024 | Scoutpro Osmolarity System, Tearlab Osmolarity System |
| Carl Zeiss Meditec USA, INC. | $1,806.42 | 2021-2025 | Veracity Surgical, Quatera 700 |
| Microsurgical Technology, INC. | $1,636.98 | 2024 | |
| Dompe US, INC. | $1,453.81 | 2020-2025 | Oxervate |
| Rxsight INC | $1,438.74 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Apellis Pharmaceuticals, INC. | $1,195.50 | 2023 | |
| Kala Pharmaceuticals, INC. | $1,164.93 | 2019-2021 | |
| Quidel Corporation | $1,129.01 | 2021-2022 | |
| Glaukos Corporation | $532.39 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Sun Pharmaceutical Industries INC. | $500.15 | 2019-2024 | Bromsite, Cequa, Xelpros |
| Eyevance Pharmaceuticals LLC | $479.13 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $342.88 | 2019-2024 | Tecnis Simplicity |
| Biotissue Holdings INC. | $333.65 | 2024-2025 | |
| Oyster Point Pharma, INC. | $271.02 | 2022-2023 | Tyrvaya |
| New World Medical,INC. | $133.58 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $126.96 | 2023-2024 | Eylea Hd |
| Ani Pharmaceuticals, INC. | $109.21 | 2025 | Purified Cortrophin Gel |
| Bausch Health US, LLC | $102.44 | 2020 | |
| Aerie Pharmaceuticals, INC. | $101.71 | 2019 | |
| Harrow Eye, LLC | $66.46 | 2024-2025 | Flarex, Iheezo, Tobradex St |
| Regeneron Pharmaceuticals, INC. | $50.03 | 2023 | Eylea |
| Nova Eye, INC. | $30.44 | 2024 | |
| Alimera Sciences, INC. | $21.47 | 2023 | Iluvien |
| Genentech USA, INC. | $19.81 | 2024 | Vabysmo |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $13.37 | 2019 | |
| Oculus Surgical INC. | $12.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$10,077.67 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathleen Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.